{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The identification of a novel mutation (E46K) in one of the KTKEGV-type repeats in the amino-terminal region of -synuclein suggests that this region and, more specifically, Glu residues in the repeats may be important in regulating the ability of -synuclein to polymerize into amyloid fibrils.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that mutations in the KTKEGV repeats, specifically Glu residues, influence amyloid fibril formation, which is central to the pathogenesis of synucleinopathies.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "It was demonstrated that the E46K mutation increased the propensity of -synuclein to fibrillize, but this effect was less than that of the A53T mutation.",
          "judgment": "Yes",
          "reasoning": "The assay described (assessment of fibrillization propensity) is a relevant assay for studying the polymerization defects in -synuclein, consistent with the described mechanism of amyloid fibril formation.",
          "next_step_or_outcome": "Proceed to Step 1.3a"
        },
        {
          "step_name": "Step 1.3a: Basic Controls and Replicates.",
          "extracted_paper_info": "It was demonstrated that the E46K mutation increased the propensity of -synuclein to fibrillize, but this effect was less than that of the A53T mutation.",
          "judgment": "No",
          "reasoning": "While the paper compares the E46K variant with A53T mutation to gauge the strength of the mutationâ€™s effect, it does not provide explicit descriptions of wild-type controls or multiple replicates.",
          "next_step_or_outcome": "Proceed to Step 1.3b"
        },
        {
          "step_name": "Step 1.3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 1.3a).",
          "extracted_paper_info": "The identification of a novel mutation (E46K) in one of the KTKEGV-type repeats in the amino-terminal region of -synuclein suggests that this region and, more specifically, Glu residues in the repeats may be important in regulating the ability of -synuclein to polymerize into amyloid fibrils.",
          "judgment": "No",
          "reasoning": "The study describes a newly observed mutation, implying that the assay is not a broadly accepted standard. There is no description of prior validation.",
          "next_step_or_outcome": "Proceed to Step 1.3c"
        },
        {
          "step_name": "Step 1.3c: Variant Controls",
          "extracted_paper_info": "It was demonstrated that the E46K mutation increased the propensity of -synuclein to fibrillize, but this effect was less than that of the A53T mutation.",
          "judgment": "No",
          "reasoning": "There were no explicit descriptions of pathogenic or benign variant controls used within the experiments.",
          "next_step_or_outcome": "Proceed to Step 3.1"
        }
      ],
      "final_interpretation": {
        "evidence_strength": "Max PS3_supporting",
        "reasoning": "Due to the lack of explicit descriptions of the controls, replicates, validation and variant control, the functional evidence strength is classified as Max PS3_supporting."
      }
    }
  ]
}